VESPER-SWITCH: monthly berobenatide for weight maintenance

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT07845500
StatusRecruiting
PhasePhase 3
SponsorPfizer
Enrollment660 participants
DesignNot stated
ConditionsObesity; Overweight
InterventionsSemaglutide; Berobenatide; Tirzepatide
StartSep 30, 2026
Primary completionFeb 16, 2028
Study completionNot stated
Results postedNot yet
Registry last updatedNot stated

Source: ClinicalTrials.gov (U.S. National Library of Medicine). See the trial changes feed for what has changed recently.

Share thisFacebookXEmail